AU2006238877A1 - Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes - Google Patents

Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes Download PDF

Info

Publication number
AU2006238877A1
AU2006238877A1 AU2006238877A AU2006238877A AU2006238877A1 AU 2006238877 A1 AU2006238877 A1 AU 2006238877A1 AU 2006238877 A AU2006238877 A AU 2006238877A AU 2006238877 A AU2006238877 A AU 2006238877A AU 2006238877 A1 AU2006238877 A1 AU 2006238877A1
Authority
AU
Australia
Prior art keywords
administering
liposomes
patient
ovarian cancer
comprises administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006238877A
Other languages
English (en)
Inventor
Ronald D. Alvarez
Michael J. Straughn Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AU2006238877A1 publication Critical patent/AU2006238877A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2006238877A 2005-04-21 2006-04-20 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes Abandoned AU2006238877A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67418805P 2005-04-21 2005-04-21
US60/674,188 2005-04-21
PCT/US2006/015528 WO2006116341A1 (en) 2005-04-21 2006-04-20 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

Publications (1)

Publication Number Publication Date
AU2006238877A1 true AU2006238877A1 (en) 2006-11-02

Family

ID=36811891

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006238877A Abandoned AU2006238877A1 (en) 2005-04-21 2006-04-20 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

Country Status (11)

Country Link
US (1) US20070026060A1 (enExample)
EP (1) EP1874324A1 (enExample)
JP (1) JP2008538584A (enExample)
KR (1) KR20080008367A (enExample)
CN (1) CN101163485A (enExample)
AU (1) AU2006238877A1 (enExample)
BR (1) BRPI0609939A2 (enExample)
CA (1) CA2605669A1 (enExample)
IL (1) IL186699A0 (enExample)
MX (1) MX2007013056A (enExample)
WO (1) WO2006116341A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
EP3693473B1 (en) 2011-06-17 2025-02-19 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
UY34295A (es) * 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
DK3415915T3 (da) 2012-02-23 2024-11-04 Childrens Medical Center Fremgangsmåde til at forudsige respons til PARP-inhibitorer
AU2013273466B2 (en) 2012-06-07 2018-11-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2946251T3 (es) 2014-08-15 2023-07-14 Myriad Genetics Inc Métodos y materiales para evaluar la deficiencia de recombinación homóloga

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
WO2001032145A1 (en) * 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment

Also Published As

Publication number Publication date
MX2007013056A (es) 2008-04-07
CN101163485A (zh) 2008-04-16
JP2008538584A (ja) 2008-10-30
BRPI0609939A2 (pt) 2010-05-11
WO2006116341A1 (en) 2006-11-02
CA2605669A1 (en) 2006-11-02
US20070026060A1 (en) 2007-02-01
KR20080008367A (ko) 2008-01-23
EP1874324A1 (en) 2008-01-09
IL186699A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
Hasovits et al. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics
Baas et al. Caelyx™ in malignant mesothelioma: A phase II EORTC study
Howell et al. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Yun et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
US20070026060A1 (en) Method for treating advanced ovarian cancer
Orditura et al. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity
Rivera et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
Kirmani et al. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
Pectasides et al. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer
De Lena et al. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
Aigner et al. Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer-a phase II study on 265 cases
WO2001083020A1 (en) Antineoplastic platinum therapeutic method and composition
EP1796689A1 (en) Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
JP2020521004A (ja) ｃ（ＲＧＤ−ＡＣＰ−Ｋ）修飾血中滞留型リポソーム
Recchia et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer
Scheithauer et al. Phase II study of amonafide in advanced breast cancer
Vermorken The role of intraperitoneal chemotherapy in epithelial ovarian cancer
Chambers et al. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
Schütte et al. 191 Phase II trial of paclitaxel and carboplatin as first line treatment in advanced non small cell lung-cancer (NSCLS)
Kalbakis et al. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
Mougenot et al. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer
Golden et al. Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes
Haddad et al. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer
Maeta et al. Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers
CN116407548A (zh) 一种蒽环类抗肿瘤药和铂类抗肿瘤药的组合物及其制备方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application